Stock Detail
LA JOLLA PHARMACEUTICAL
Drugs
LJPC @ Yahoo Finance | LJPC Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $0.03 | $0.03 | $0.00 | 0.00% | 0.00 | $0.03 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $0.00 | $0.02 | 499,809 | 0 | 0 | -0.24 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 0.04 | 0.04 | 0.03 | 0.03 | 0.02 |
Stock Profile
La Jolla Pharmaceutical Company, a biopharmaceutical company, engages in the research and development of pharmaceutical products in the United States. Its principal product in development is Riquent, which is designed to treat lupus renal disease by preventing or delaying renal flares. Lupus is an antibody-mediated disease caused by abnormal B cell production of antibodies that attack healthy tissues. Riquent is in Phase III clinical trial. The company also develops small molecules for the treatment of autoimmune diseases, and acute and chronic inflammatory disorders. La Jolla Pharmaceutical Company was founded in 1989 and is based in San Diego, California.